NCT00551070 · OUTCOME

Overall Survival

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer · Source last updated 2020-12-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Months
Interval / dispersion: 95% Confidence Interval
Time frame: Every cycle during treatment, then every 3 months for the first 2 years, then every six months for the next three years and then annually for the next 5 years

Analysis population: Eligible and Treated Patients

Groups in this outcome

AZD6244

AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
AZD6244	52

Reported measurements

Source class 1

Values in Months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
AZD6244	32.4	Not reported	17.7	39.3	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
17.7
upper Limit
39.3
value
32.4

denoms

counts
group Id
OG000
value
52
units
Participants

dispersion Type

95% Confidence Interval

groups

description
AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)
id
OG000
title
AZD6244

param Type

MEDIAN

population Description

Eligible and Treated Patients

reporting Status

POSTED

time Frame

Every cycle during treatment, then every 3 months for the first 2 years, then every six months for the next three years and then annually for the next 5 years

title

Overall Survival

type

SECONDARY

unit Of Measure

Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice